SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High - Still a Buy?

Key Points

• SELLAS (SLS) hit a new 52-week high — the stock traded as high as $5.94 (last $5.9240) on about 5.41 million shares, up from a prior close of $5.53.
• Wall Street sentiment is mixed: Weiss Ratings reiterated a "sell (d-)", one analyst has a Buy and one a Sell, giving an average rating of "Hold" with an average price target of $7.00, while institutional ownership is about 17.38% with recent buying by firms including Caitong, Invesco and XTX Topco.
• Fundamentals show a market cap of roughly $856.8 million, a negative P/E (-21.41) and a beta of 2.18, with technicals at a 50-day SMA of $4.17 vs a 200-day SMA of $2.66; the company is a clinical-stage biopharma focused on WT1-targeted immunotherapies, led by the investigational vaccine galinpepimut-S (GPS).

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $5.94 and last traded at $5.9240, with a volume of 5409885 shares traded. The stock had previously closed at $5.53.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $7.00.

SELLAS Life Sciences Group Stock Performance

The stock has a market cap of $856.79 million, a PE ratio of -21.41 and a beta of 2.18. The company's 50 day simple moving average is $4.17 and its 200 day simple moving average is $2.66.

Institutional Trading of SELLAS Life Sciences Group

A number of hedge funds have recently bought and sold shares of SLS. Caitong International Asset Management Co. Ltd boosted its position in SELLAS Life Sciences Group by 408.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 55,129 shares of the company's stock worth $208,000 after purchasing an additional 44,296 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of SELLAS Life Sciences Group by 6.2% in the 4th quarter. Invesco Ltd. now owns 53,293 shares of the company's stock worth $201,000 after buying an additional 3,114 shares during the last quarter. Axxcess Wealth Management LLC grew its position in SELLAS Life Sciences Group by 121.1% during the fourth quarter. Axxcess Wealth Management LLC now owns 35,370 shares of the company's stock valued at $133,000 after buying an additional 19,370 shares during the period. Beacon Pointe Advisors LLC purchased a new stake in SELLAS Life Sciences Group during the fourth quarter worth about $38,000. Finally, XTX Topco Ltd purchased a new stake in SELLAS Life Sciences Group during the fourth quarter worth about $447,000. 17.38% of the stock is currently owned by institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.